Introduction
============

Respiratory syncytial virus related lower respiratory tract infection is the most common cause of infants being admitted to hospital during winter and is often followed by recurrent transient episodes of wheeze.[@ref1] [@ref2] [@ref3] Recurrent wheeze after respiratory syncytial virus infection has a high prevalence,[@ref4] influences quality of life,[@ref5] and generates substantial healthcare costs.[@ref6]

It has been hypothesised that the infection and concomitant inflammatory reaction in the acute phase of the infection leads to recurrent wheeze.[@ref7] In line with this hypothesis, immune modulation during the acute phase might influence recurrent wheeze. Evidence on the effectiveness of early anti-inflammatory therapy in the prevention of recurrent wheeze is conflicting,[@ref8] [@ref9] [@ref10] and the use of inhaled glucocorticoids varies greatly among countries.[@ref11] [@ref12] [@ref13] [@ref14] [@ref15] Thirty per cent of paediatricians in Switzerland reported that they always start inhaled glucocorticoids in patients admitted to hospital with respiratory syncytial virus related lower respiratory tract infection whereas 11% of paediatricians in Ireland selected such treatment in the case of a three month old infant with moderately severe disease.[@ref14] [@ref15] No large trials have studied the effect of inhaled glucocorticoids on recurrent wheeze after respiratory syncytial virus infection,[@ref16] preventing strong recommendations on the use of inhaled glucocorticoids. We carried out a large randomised double blind placebo controlled trial to investigate whether early initiated high dose extra fine hydrofluoroalkane (HFA) beclometasone diproprionate for three months after admission to hospital for respiratory syncytial virus infection prevents recurrent wheeze.

Methods
=======

The RSV Corticosteroid Study is a multicentre, randomised double blind placebo controlled trial comparing early initiated high dose extra fine HFA beclometasone with placebo in infants aged less than 13 months admitted to hospital for lower respiratory tract infection and with a positive immunofluorescence result for respiratory syncytial infection in epithelial cells from nasopharyngeal aspirates. We excluded infants who had previously been given steroids, had a history of cardiac or pulmonary disease, or had had a previous illness with wheeze. Recruitment took place during the winter seasons from November 2004 to February 2006 in the paediatric departments of 19 clinical centres in the Netherlands. Written informed consent was obtained from the infants' parents. Good clinical practice guidelines were followed.

Randomisation
-------------

Eligible infants were randomly assigned to receive either extra fine HFA beclometasone dipropionate or placebo. Randomisation was by means of a computer generated list of six numbers in each block and fixed blocks within each hospital. Local investigators at the paediatric departments enrolled infants and provided boxes containing the allocated treatment. Blinding was achieved by using active and placebo drugs of identical shape and taste. The doctors, nurses, parents, and investigators were unaware of the randomisation codes until data entry was complete.

Study intervention
------------------

Interventions were 200 μg extra fine HFA beclometasone dipropionate (Qvar; 3M, TevaPharma, Haarlem, the Netherlands) twice daily or matching placebo given by pressurised metered dose inhalers and a spacer (Aerochamber; Trudell International Europe, Nottingham). The extra fine beclometasone formulation has smaller particles than conventional inhaled glucocortiocosteroids and is possibly more effective.[@ref17] Treatment was started within 24 hours of respiratory syncytial virus being detected and continued for three months. Treatment in infants with severe disease who needed mechanical ventilation was started within 24 hours of extubation. Asthma nurses taught the patients' parents correct inhaler techniques. Parental competence was evaluated three weeks after hospital discharge in 177 infants. Performance was scored on six items according to modified criteria of the Dutch Asthma Foundation[@ref18] (shaking of the inhaler, correct assembly of spacer and canister, activation of the canister, no more than three puffs at the same time, inhalation during at least 10 seconds, moving spacer valve). Median scores for performance in both groups were 6 (interquartile range 5-6).

Infants were followed up for one year after completion of treatment, during which time we determined the number of days with wheeze (the primary outcome measure). At the discretion of the paediatricians at the clinical centres, open label bronchodilators could be added to the study treatment if required. If steroid therapy was necessary, study treatment was discontinued.

Primary and secondary outcome measures
--------------------------------------

Parents recorded airway symptoms and the use of airway drugs in a daily log.[@ref19] The logs were kept for 15 months from the start of intervention. They were returned to the investigators every three months. Parents were instructed how to complete the logs by a single investigator and telephone calls were scheduled every three months for motivational purposes.

The primary outcome was the number of days with wheeze. Secondary outcomes were the number of days with cough, the number of days using airway drugs, duration of hospital stay, health related quality of life, lung function, potential adverse effects of treatment on growth, and incidence of thrush. We assessed health related quality of life with the TNO-AZL preschool children quality of life questionnaire[@ref20] during the winter season one year after admission to hospital. The infants were tested for lung function and bronchial responsiveness at age 2 years by measuring interrupter resistance using a transducer (MicroRint; Micro Medical, Rochester, Kent). The interrupter technique measures changes in mouth pressure after a brief interruption of airflow at the mouth. It is based on the principle that the alveolar pressure and mouth pressure equilibrate within a few milliseconds of brief interruption of airflow. Airway resistance can be calculated from the ratio of mouth pressure to airflow at the mouth just before occlusion,[@ref21] and this was measured before and after administration of 400 μg of inhaled salbutamol using a spacer. Growth was evaluated by measuring height at age 2 years.

To obtain data on respiratory symptoms, allergy, parental smoking, and allergy symptoms among first degree family members we used an extended Dutch version of the standardised questionnaire of the British Medical Research Council and the Dutch version of the European community respiratory health survey questionnaire.[@ref22] [@ref23]

Statistical analysis
--------------------

The sample size was based on prevalence data for the primary outcome obtained from our previous follow-up study on respiratory syncytial virus bronchiolitis.[@ref19] In that cohort, 80% of infants wheezed at any time, with a mean number of days with wheeze during the 4 to 15 months after infection of 34.2 (95% confidence interval 26.2 to 42.3 days). The predefined target of 250 patients provided at least 90% power to detect a clinically relevant difference of 14 days with wheeze between both arms.

We analysed the effects of beclometasone on the occurrence of any wheeze, cough, use of airway drugs, and thrush during follow-up. Percentages and associated 95% confidence intervals of infants with any symptoms were calculated. We counted the number of days with symptoms or drug use, or both, to evaluate the effect of treatment on the severity of wheeze, cough, and drug use. As a typical Poisson distribution for probability arose we used Poisson regression analysis to study potential differences in number of days with wheeze and cough and in days of airway drug use. Duration of hospital stay (days), quality of life domain scores, measurements of interrupter resistance (kPA/L/s), and height (cm) are expressed as medians and means. We used χ^2^ tests, Student's *t* tests, and Mann Whitney U test to evaluate differences in percentages, mean values, and median values between the groups. To detect possible effect modification we carried out two prespecified subgroup analyses---the need for mechanical ventilation (yes *v* no) and the presence of signs indicating airflow limitation during initial respiratory syncytial virus infection---that is, doctor diagnosed wheeze by auscultation (yes *v* no).[@ref24]

To decrease bias and increase statistical efficiency, we imputed missing data for quality of life domain scores, interrupter resistance measurements, duration of hospital stay, height, and presence of thrush. Imputation was done using the linear regression method (missing value analyses) available in SPSS for Windows version 13.0 software.[@ref25] [@ref26] Such imputation is based on the correlation between each variable with missing values and all other variables as estimated from the full dataset of participants with complete data. All analyses were done on an intention to treat basis, implying that no adjustments were made for the need for steroid treatment during the intervention period. In addition we carried out analyses on infants with complete log data (complete case analyses).

Results
=======

A total of 323 parents were asked if their child could participate in this intervention study; 78 were excluded for various reasons (previous use of steroids, cardiac history, not willing to participate). Overall, 243 infants were randomised: 119 to extra fine HFA beclometasone and 124 to placebo (fig 1[](#fig1){ref-type="fig"}). Table 1[](#tbl1){ref-type="table"} shows the baseline characteristics of both groups. During the year of observation airway symptoms were recorded for 2305 months (79% of total months). The median duration of follow-up for both groups was 15 months (interquartile range 12-15 months).

![**Fig 1** Flow of patients through study](ermm594598.f1_default){#fig1}

###### 

 Baseline characteristics of infants with respiratory syncytial virus infection randomly assigned to receive extra fine hydrofluoroalkane beclometasone or placebo. Values are percentages unless stated otherwise

  Characteristics                                                                        Beclometasone group (n=119)   Placebo group (n=124)
  -------------------------------------------------------------------------------------- ----------------------------- -----------------------
  Male                                                                                   52                            52
  White                                                                                  85                            84
  Median (interquartile range) duration of illness before admission to hospital (days)   3 (1-4)                       2 (1-4)
  Median (interquartile range) age at admission to hospital (months)                     2 (1-4)                       2 (1-5)
  Admitted to intensive care unit, needing mechanical ventilation                        9                             9
  Median (interquartile range) gestational age (weeks)                                   39.5 (37.5-40.6)              39.5 (37.5-40.6)
  Breast fed for at least one month                                                      66                            58
  Signs of airflow limitation during initial respiratory tract infection                 60                            51
  Maternal smoking before birth                                                          18                            10
  Median (interquartile range) atopy score\*                                             1 (0-3)                       1 (0-3)

\*Semiquantitative parental score for atopy. One point added to score for presence of each atopic symptom (eczema, hay fever, bronchitis, asthma, and food allergy).^27^

Airway symptoms and use of drugs during observation year
--------------------------------------------------------

Table 2[](#tbl2){ref-type="table"} shows the number of days with symptoms and the number of days using airway drugs during the year of observation. During the entire year of observation the number of days with wheeze in the total group and in the predefined subgroup of infants with signs of airway limitation during infection was similar but was lower in the subgroup of non-ventilated infants treated with beclometasone (n=221). An absolute reduction in days with wheeze of 2.1% was observed (total days, 2120/33 149 (6.4%) in the placebo group *v* 1315/30 405 (4.3%) in the beclometasone group, P=0.046), a relative reduction of 32%. Infants treated with beclometasone also had fewer days with cough. No other differences were observed. Results were similar with complete case analyses.

###### 

 Total number of days with airway symptoms and use of drugs compared with total log days during follow-up of infants with respiratory syncytial virus infection allocated to extra fine hydrofluoroalkane beclometasone or placebo

  Variables                                                                 Beclometasone group          Placebo group   P value\*   Rate ratio          
  ------------------------------------------------------------------------- --------------------- ------ --------------- ----------- ------------ ------ ------
  Total group (n=243):                                                                                                                                   
   Wheeze                                                                   33 568                1761                   36 556      2301         0.31   0.83
   Cough                                                                    7341                         9585            0.03        0.83                
   Steroid use                                                              2578                         3105            0.69        0.90                
   Bronchodilator use                                                       2066                         2749            0.39        0.82                
  No need for mechanical ventilation (n=221):                                                                                                            
   Wheeze                                                                   30 405                1315                   33 149      2120         0.05   0.68
   Cough                                                                    6681                         8724            0.05        0.83                
   Steroid use                                                              2055                         2916            0.34        0.77                
   Bronchodilator use                                                       1725                         2332            0.39        0.81                
  Signs of airflow limitation during respiratory tract infection (n=133):                                                                                
   Wheeze                                                                   19 290                1148                   18 465      916          0.41   1.20
   Cough                                                                    4084                         4377            0.37        0.89                
   Steroid use                                                              1739                         1028            0.16        1.62                
   Bronchodilator use                                                       1252                         1152            0.90        1.04                

\*Poisson regression analyses.

Figure 2[](#fig2){ref-type="fig"} shows the distribution of days with wheeze during follow-up in the two treatment groups. To gain insight into the short term effects of intervention, Poisson analyses were carried out separately for the first six months of the observation year and the second six months. These retrospective Poisson analyses showed a more pronounced reduction in the number of days with wheeze during the first six months than during the second six months in the total group (total days, 1354/19 048 (7.1%) in the placebo group *v* 949/17 664 (5.4%) in the beclometasone group, P=0.18) and in the subgroup of non-ventilated infants (total days, 1265/17 215 (7.3%) in the placebo group *v* 683/16 043 (4.3%) in the beclometasone group, P=0.02). No differences were observed in the subgroup of infants with signs of airflow limitation during infection (total days, 569/9752 (5.8%) in the placebo group *v* 599/10 116 (5.9%) in the beclometasone group, P=0.96).

![**Fig 2** Days with wheeze during observation year in total group of infants (Poisson P=0.31) and in subgroup not needing mechanical ventilation (Poisson P=0.05)](ermm594598.f2_default){#fig2}

The proportion of infants with wheeze, with cough, and using airway drugs did not differ between the placebo and beclometasone groups during follow-up (wheeze 62% *v* 61%, cough 86% *v* 83%, use of bronchodilators 42% *v* 40%, use of steroids 26% *v* 25%). Comparable results were obtained in the two predefined subgroups.

Secondary outcomes and adverse events
-------------------------------------

The median duration of hospital stay was similar in both groups (4 days (interquartile range 3-8 days) in the placebo group *v* 5 (4-8) days in the beclometasone group, P=0.07). The TNO-AZL preschool children quality of life questionnaire, completed during the winter season one year after admission to hospital, was returned by 191 parents (79%). Comparison of the domain scores for stomach problems, skin problems, lung problems, sleeping, appetite, liveliness, positive mood, problem behaviour, anxiety, social functioning, motor functioning, and communication showed that infants in the beclometasone group had lower scores for appetite than infants in the placebo group (median score 67 (intequartile range 50-100) *v* 83 (50-100), P=0.03). At the end of the study, weight did not differ between the groups.

Measurement of airways resistance during the summer season in 2 year olds was successfully carried out in 91 of 163 children (56%). No differences were found in percentage of successful measurements, baseline interrupter resistance, and interrupter resistance after inhalation of salbutamol between the two treatment groups (mean baseline interrupter resistance 1.15 kPA/L/s (95% confidence interval 1.10 to 1.19 kPA/L/s) in the placebo group *v* 1.10 kPA/L/s (1.03 to 1.17) in the beclometasone group, P=0.9).

No severe adverse events were reported. Two infants in the beclometasone group had treatment stopped prematurely because of repeated thrush during the intervention period; however, the number of infants with thrush was similar in both groups (41/124 in the placebo group *v* 47/119 in the beclometasone group, odds ratio 1.3 (95% confidence interval 0.8 to 2.2), P=0.3). Height at age 2 was similar in both groups (mean 86.8 cm (95% confidence interval 86.2 to 87.5 cm) in placebo group *v* mean 86.9 cm (86.2 to 87.7), P=0.8) in beclometasone group.

Discussion
==========

Early initiated high dose extra fine HFA beclometasone given to infants (\<13 months) for three months after respiratory syncytial virus related lower respiratory tract infection did not prevent recurrent wheeze. The number of days with wheeze in infants who did not require mechanical ventilation during infection showed a modest reduction from 6.4% to 4.3%; a relative reduction of 32%. No positive effect of our intervention on health related quality of life was observed. We found no evidence of side effects with the intervention.

Comparison with other studies
-----------------------------

No treatment during lower respiratory tract infections caused by respiratory syncytial virus has been shown convincingly to have a beneficial effect on the course of acute disease or on long term airways morbidity. A beneficial effect of leukotriene receptor antagonists was suggested[@ref28] but could not be replicated in a large double blind study.[@ref29] The current trial was based on the hypothesis that early initiated high dose inhaled glucocorticoids modify the immune response after respiratory syncytial virus infection resulting in the reduction of recurrent wheeze. Although studies suggest that about one quarter of infants admitted to hospital with bronchiolitis receive corticosteroids,[@ref30] [@ref31] the efficacy of these agents has not been shown consistently. Several studies have shown that corticosteroids are not effective in the acute treatment of respiratory syncytial virus infections.[@ref32] [@ref33] [@ref34] [@ref35] A randomised controlled trial carried out in a birth cohort at risk of asthma found no effect of inhaled glucocorticoids on the progression of episodic wheeze into persistent wheeze.[@ref36] In addition, no disease modifying effect of a two year therapy of inhaled corticosteroids was observed in a third, treatment-free year in preschool children at high risk of asthma.[@ref37] The temporary effects of inhaled steroids in that study and our study are similar. The role of inhaled glucocorticoids in the prevention of recurrent wheeze after respiratory syncytial virus infection is of particular interest because the pathogenesis of such infections is thought to be distinct from that of other wheezing disorders in infancy.[@ref38] Episodic high doses of inhaled glucocorticoids have been shown to provide a partially effective strategy in children with episodic wheeze caused by viruses.[@ref39] Previous studies investigating whether inhaled glucocorticoids can reduce the occurrence of recurrent wheeze after respiratory syncytial virus infection have yielded conflicting data and had major limitations, including small sample size, low dosage of treatment, mean age older than 12 months at inclusion, and lack of accurate tools to measure long term airways morbidity.[@ref10] [@ref16] [@ref27] [@ref40] [@ref41] [@ref42]

Strengths and limitations of study
----------------------------------

The major strength of our study is that high dose treatment with beclometasone was initiated early, within 24 hours of the diagnosis of respiratory syncytial virus infection. Furthermore, the effect on recurrent wheeze was specifically evaluated in the group of infants admitted to hospital because of respiratory syncytial virus infection. To our knowledge this is the first randomised controlled trial that was sufficiently powered to evaluate the effect of early high dose inhaled glucocorticoids on recurrent wheeze after respiratory syncytial virus infection.

Some of our findings merit further discussion. Firstly, the data suggest that inhaled beclometasone did not prevent or diminish recurrent wheeze after respiratory syncytial virus infection in the total group of infants. No decrease in the number of days with wheeze and a small decrease in the number of days with cough were observed. Quality of life scores and interrupter resistance did not differ between the beclometasone and placebo groups. However, the study might be confounded because infants with severe disease who needed mechanical ventilation were analysed along with infants with more mild disease who did not need mechanical ventilation. No benefit of inhaled beclometasone was observed in mechanically ventilated infants. The small number of infants in this subgroup impedes a conclusion about the effect of inhaled beclometasone on recurrent wheeze in ventilated infants. However, we speculate that the delayed start of treatment prevented a treatment induced modification of the disease's course. Furthermore, it is possible that infants with severe disease did not respond to inhaled beclometasone as a result of mechanical injury during supportive care or because of enhanced virus mediated lung damage at the time of the initial process. In the major subgroup of infants (n=221) who did not need mechanical ventilation the number of days with wheeze fell from 6.4% to 4.3%, a relative reduction of 32%. The effect of inhaled beclometasone was most pronounced during the first six months after treatment. The beneficial effect of beclometasone that was observed in the short term might be due to reduced airway reactivity during that period. No differences in quality of life scores and interrupter resistance were observed between the two groups, measured at a time when the severity of wheeze was similar in both groups. Because the TNO-AZL preschool children quality of life questionnaire measures health related quality of life over the past three months only, the outcome might have been different if measurements were taken earlier.

Secondly, we found treatment with beclometasone to be ineffective in infants presenting with signs of airflow limitation during respiratory syncytial virus infection, a subgroup reported to be at increased risk of developing recurrent wheeze.[@ref24] This finding seems counterintuitive. The disease modifying effect of beclometasone on recurrent wheeze after respiratory syncytial virus infection might be limited to specific phenotypes. The relevance of the presence of signs of airflow limitation during such infection to both the development of recurrent wheeze and the effect of treatment needs further research.

Thirdly, the results might have been influenced by inadequate administration of and adherence to the drugs. However, most parents carried out all essential steps correctly for administering the drugs. Moreover, a sensitivity analysis for infants whose parents carried out all steps correctly did not change the results. We determined parental adherence to the treatment regimen in a subset of infants by weighing returned canisters. Most parents gave the prescribed drug twice daily during at least nine full weeks of the prescribed three months.

Fourthly, this study was powered to detect a difference of 14 days between both treatment arms. The difference of 14 days with wheeze was arbitrarily defined and we might have missed a smaller but important effect. The power was based on mean differences whereas we finally used Poisson regression analysis to study differences in numbers of days with wheeze, which detects smaller differences as statistically significant.

Fifthly, no other research group externally validated the logs kept by the parents. We used the logs in two groups and observed that the occurrence of wheeze was virtually identical between the groups. This similarity supported the internal validity of the information from the logs. Finally, not all parents returned complete log data for the follow-up period, and thus the selective loss of data could have biased the results. However, complete case analysis gave similar results, the response rate in this trial was high, and missing data were equally distributed over both treatment groups.

Conclusions and policy implications
-----------------------------------

A Cochrane review on inhaled corticosteroids in the prevention of recurrent wheeze could not provide strong recommendations because of the small number of participants and the inability to pool all clinical outcomes.[@ref16] We found that early initiated high dose extra fine HFA beclometasone in infants aged less than 13 months during the first three months after admission to hospital for respiratory syncytial virus infection did not reduce the severity of recurrent wheeze. Only in our a priori specified subgroup of non-ventilated children was a modest and temporary reduction in days with wheeze found. We therefore conclude that general use of early initiated high dose extra fine HFA beclometasone should not be advised in infants admitted to hospital for respiratory syncytial virus infections.

### What is already known on this topic

1.  Evidence on the effectiveness of early anti-inflammatory treatment to prevent recurrent wheeze is conflicting

2.  Despite this, inhaled glucocorticoids are in common use

### What this study adds

1.  Early initiated high dose beclometasone in infants in the three months after hospital admission for respiratory syncytial virus infection has no major effect on recurrent wheeze
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